NCT01829217 2018-10-31
Sunitinib in Never-Smokers With Lung Adenocarcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
9 trialsNCT00748163 2018-08-08
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT00953459 2018-07-26
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01402089 2016-02-02
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Cantonal Hospital of St. Gallen
Phase 4 Completed
NCT00620347 2013-06-19
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT01850147 2013-05-09
Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
ChineseAMS
Phase 2 Unknown
NCT00430261 2010-10-06
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Swedish Medical Center
Phase 2 Completed
NCT00113516 2010-05-18
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00712504 2008-11-11
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
Pfizer
Phase 1 Completed